Menu

Peanut Allergy Treatment Works Long Term

Four years after taking a probiotic and peanut protein for 18 months, two-thirds of children in a small clinical trial can eat peanuts with no health issues.

Aug 17, 2017
Jef Akst

FLICKR, AIRPIXIn 2013, researchers at Murdoch Children’s Research Institute in Australia dosed 48 children either with a probiotic with increasing amounts of a peanut protein, a treatment known as PPOIT, or with a placebo once daily for a year and a half. This week (August 15), they reported that some 70 percent of the participants who received PPOIT can ingest peanut-containing foods with no adverse reactions, according to a study published in The Lancet Child & Adolescent Health.

That result represents only a slight dip from the original results that found 82 percent of the treated children could tolerate peanuts one month after finishing their PPOIT courses, suggesting the treatment is the first long-lasting option for those who suffer from a peanut allergy.

“These children had been eating peanut freely in their diet without having to follow any particular program of peanut intake in the years after treatment was completed,” lead researcher Mimi Tang says in a statement sent to The Scientist. “This is a major step forward in identifying an effective treatment to address the food allergy problem in Western societies.”

The probiotic used was Lactobacillus rhamnosus, a bacterium that may help mitigate allergic symptoms. “The probiotic acts on the immune system, encourages the immune system to generate a protective, or tolerance, response rather than allergy,” says Tang, according to ABC. “When given regularly over time, we hope to see the immune system recognise the antigen.” The next step is to trial PPOIT in a larger study. 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.